𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Predictors of treatment outcome in headache patients with the Millon Clinical Multiaxial Inventory III (MCMI-III)

✍ Scribed by J. S. Hansen; L. Bendtsen; R. Jensen

Publisher
Springer
Year
2007
Tongue
English
Weight
128 KB
Volume
8
Category
Article
ISSN
1129-2369

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Millon Clinical Multiaxial Inventory (MC
Millon Clinical Multiaxial Inventory (MCMI-III): The inability of the validity conditions to detect random responders
✍ Richard A. Charter; Michael N. Lopez πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 52 KB

## Abstract The effectiveness of the MCMI‐III Validity scale, Scale X, and the Clinical Personality Pattern scales to detect random responding is put to the test. The binomial expansion and Monte Carlo techniques were used. If the examiner is willing to interpret tests of questionable validity, the

Discriminant validity of the illness beh
Discriminant validity of the illness behavior questionnaire and millon clinical multiaxial inventory-III in a heterogeneous sample of psychiatric outpatients
✍ Gregory J. Boyle; LoΓ―ck Le DΓ©an πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 198 KB πŸ‘ 2 views

The discriminant validity of measures of abnormal illness behaviors and psychopathology was examined in three samples differing in illness proneness: a sample of young healthy university students (n Ο­ 38), a general community sample (n Ο­ 36), and a sample of clinical psychiatric outpatients (n Ο­ 36)

Humoral response to catumaxomab correlat
Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II/III study in patients with malignant ascites
✍ Marion G. Ott; Frederik MarmΓ©; Gerhard Moldenhauer; Horst Lindhofer; Michael Hen πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 French βš– 893 KB

The trifunctional antibody catumaxomab is a targeted immunotherapy for the intraperitoneal treatment of malignant ascites. In a Phase II/III trial in cancer patients (__n__ = 258) with malignant ascites, catumaxomab showed a clear clinical benefit __vs__. paracentesis and had an acceptable safety pr

The addition of interferon or high dose
The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma : Phase III Eastern Cooperative Oncology Group clinical trial EST 9486
✍ Martin M. Oken; Traci Leong; Raymond E. Lenhard Jr.; Philip R. Greipp; Neil E. K πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 133 KB πŸ‘ 2 views

## BACKGROUND. Interferon (IFN) has demonstrated activity in the treatment of patients with multiple myeloma. A previous Eastern Cooperative Oncology Group (ECOG) study suggested that the rates of complete response (CR) and survival were increased with a regimen that alternated IFN with chemothera